Get the Stockscreener App
1.24
1.59%
-0.02
After Hours:
1.23
-0.01
-0.81%
Cognition Therapeutics Inc stock is traded at $1.24, with a volume of 834.24K.
It is down -1.59% in the last 24 hours and down -3.13% over the past month.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).
See More
Previous Close:
$1.26
Open:
$1.26
24h Volume:
834.24K
Relative Volume:
0.78
Market Cap:
$110.98M
Revenue:
-
Net Income/Loss:
$-23.49M
P/E Ratio:
-3.6078
EPS:
-0.3437
Net Cash Flow:
$-24.59M
1W Performance:
+11.71%
1M Performance:
-3.13%
6M Performance:
-24.85%
1Y Performance:
+317.65%
1-Day Range:
$1.2209
$1.30
1-Week Range:
$1.09
$1.30
52-Week Range:
$0.2223
$3.83
Cognition Therapeutics Inc Stock (CGTX) Company Profile
Name
Cognition Therapeutics Inc
Sector
Industry
Phone
412-481-2210
Address
2500 WESTCHESTER AVE, PURCHASE
Compare CGTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CGTX
Cognition Therapeutics Inc
|
1.24 | 112.77M | 0 | -23.49M | -24.59M | -0.3437 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cognition Therapeutics Inc Stock (CGTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-24 | Upgrade | B. Riley Securities | Neutral → Buy |
| Jul-30-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-03-21 | Initiated | B. Riley Securities | Buy |
| Nov-03-21 | Initiated | Oppenheimer | Outperform |
Cognition Therapeutics Inc Stock (CGTX) Latest News
Cognition Therapeutics Advances Zervimesine (CT1812) Toward Registrational Trial for Dementia with Lewy Bodies Psychosis After Positive FDA Meeting - Minichart
Cognition Therapeutics discusses FDA meeting on DLB drug trial - Investing.com
Cognition Therapeutics Advances Zervimesine Toward Late-Stage DLB Trial - TipRanks
Cognition Therapeutics discusses FDA meeting on DLB drug trial By Investing.com - Investing.com Canada
Cognition Therapeutics, Inc. Reports Positive FDA Meeting on Zervimesine Development for Dementia with Lewy Bodies Psychosis - Quiver Quantitative
Cognition Therapeutics completes FDA meeting, sees path for registrational DLB psychosis program - TradingView
Cognition Therapeutics (CGTX) outlines FDA path for zervimesine DLB psychosis trial - Stock Titan
FDA, Cognition discuss next trial for Lewy body dementia psychosis drug - Stock Titan
Cognition Therapeutics, Inc.Common Stock (NQ: CGTX - The Chronicle-Journal
CGTX Should I Buy - Intellectia AI
Cognition Therapeutics receives donation to extend DLB program By Investing.com - Investing.com Australia
Cognition Therapeutics receives donation to extend DLB program - Investing.com
Cognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies - The Manila Times
Donor extends 2-year access to experimental DLB therapy for 32 people - Stock Titan
Press Release: Cognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine (CT1812) in Dementia With Lewy Bodies - Moomoo
CGTX Technical Analysis | Trend, Signals & Chart Patterns | COGNITION THERAPEUTICS INC (NASDAQ:CGTX) - ChartMill
Chardan Capital Maintains Cognition Therapeutics(CGTX.US) With Buy Rating, Cuts Target Price to $4 - Moomoo
COGNITION THERAPEUTICS INC 1Q 2026: Net income $(4.57M), EPS $(0.05) — 10-Q Summary - TradingView
Cognition Therapeutics (NASDAQ: CGTX) Q1 2026 loss narrows on lower R&D - Stock Titan
Cognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business Update - The Manila Times
Cognition Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Cognition Therapeutics (NASDAQ: CGTX) cuts Q1 2026 loss and projects cash runway into Q2 2027 - Stock Titan
Dementia-drug developer gets May 20 FDA meeting as 2027 data loom - Stock Titan
Cognition Therapeutics (NASDAQ: CGTX) CFO has 8,567 shares withheld for taxes - Stock Titan
Cognition Therapeutics Inc expected to post a loss of 7 cents a shareEarnings Preview - TradingView
Cognition Therapeutics (CGTX) to Release Earnings on Wednesday - MarketBeat
Cognition Therapeutics | DEF 14A: Definitive information statements - Moomoo
Cognition Therapeutics | DEFA14A: Others - Moomoo
Cognition Therapeutics | ARS: Annual Report to Security Holders - Moomoo
[ARS] COGNITION THERAPEUTICS INC SEC Filing - Stock Titan
Cognition Therapeutics (NASDAQ: CGTX) outlines 2026 virtual meeting, director elections and EY ratification - Stock Titan
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Cognition therapeutics CMO buys $11,100 in common stock - Investing.com India
Cognition Therapeutics, Inc. (CGTX) - Minichart
Top Brass Makes Bold Move With Fresh Insider Buying Spree at Cognition Therapeutics - TipRanks
Insider Buying: John Doyle Acquires 10,000 Shares of Cognition T - GuruFocus
John Brendan Doyle Purchases 10,000 Shares of Cognition Therapeutics (NASDAQ:CGTX) Stock - MarketBeat
Lisa Ricciardi Acquires 9,175 Shares of Cognition Therapeutics (NASDAQ:CGTX) Stock - MarketBeat
Cognition therapeutics CFO John Doyle buys $11,299 in stock - Investing.com
Cognition therapeutics CEO Lisa Ricciardi buys $10,092 in shares - Investing.com
Cognition therapeutics CEO Lisa Ricciardi buys $10,092 in shares By Investing.com - Investing.com India
Cognition therapeutics CFO John Doyle buys $11,299 in stock By Investing.com - Investing.com South Africa
Cognition therapeutics CMO buys $11,100 in common stock By Investing.com - Investing.com Canada
Cognition Therapeutics (CGTX) CFO adds 10,000 shares in open-market buy - Stock Titan
Cognition Therapeutics (CGTX) CEO buys 9,175 open-market shares - Stock Titan
Insider buy: Cognition Therapeutics (CGTX) CMO adds 10,000 shares - Stock Titan
Cognition Therapeutics (CGTX.US) achieved positive results in the CT1812 trial for Alzheimer's disease medication. - 富途牛牛
CGTX: Phase III trials for zervimesine in DLB psychosis and Alzheimer's are advancing with strong safety and efficacy data - TradingView
Cognition Therapeutics Targets Faster DLB Psychosis Path as Zervimesine Nears Late-Stage Plans - Yahoo Finance
Update Report: Can Cognition Therapeutics Inc disrupt its industryQuarterly Trade Summary & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn
Insider Trends: Whats the fair value of Cognition Therapeutics Inc stockSell Signal & Real-Time Market Sentiment Reports - baoquankhu1.vn
Cognition Therapeutics Inc Stock (CGTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):